ArticleJournal of Cancer2023

High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma.

Youngun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.